论文部分内容阅读
目的:探究阿帕替尼联合替吉奥胶囊治疗晚期复发转移食管癌患者的疗效。方法:选择2017年1月至2019年1月于山东省泰安市肿瘤防治院就诊的140例晚期食管癌患者作为研究对象，采用随机数表法将患者随机分为观察组(72例)和对照组(68例)，观察组给予阿帕替尼联合替吉奥化疗，对照组仅给予替吉奥化疗，观察两组患者近远期疗效及不良反应。结果:观察组客观缓解率为38.9%(28/72)，明显优于对照组的22.1%(15/68)，差异有统计学意义(n χ2＝4.655，n P＝0.031)；观察组疾病控制率为88.9%(64/72)，明显优于对照组的61.8%(42/68)，差异有统计学意义(n χ2＝13.993，n P<0.001)。观察组和对照组中位无进展生存期分别为5.9个月、2.7个月，中位总生存期分别为14.8个月、7.9个月，两组比较差异均有统计学意义(n χ2＝5.477，n P＝0.026；n χ2＝6.083，n P＝0.014)。两组患者不良反应均较轻，为1～2级，主要有乏力、白细胞减少、手足综合征、高血压、蛋白尿，观察组发生率分别为59.7%(43/72)、50.0%(36/72)、8.3%(6/72)、12.5%(9/72)、9.7%(7/72)，对照组发生率分别为51.5%(35/68)、57.4%(39/68)、17.6%(12/68)、4.4%(3/68)、4.4%(3/68)，两组比较差异均无统计学意义(n χ2＝0.965，n P＝0.326；n χ2＝0.760，n P＝0.383；n χ2＝2.708，n P＝0.100；n χ2＝2.919，n P＝0.088；n χ2＝0.794，n P＝0.373)。n 结论:阿帕替尼联合替吉奥对复发转移食管癌治疗疗效较好，安全性及耐受性可。“,”Objective:To explore the efficacy of apatinib combined with S-1 capsule in the treatment of patients with advanced recurrent and metastatic esophageal cancer.Methods:A total of 140 patients with advanced esophageal cancer were selected as test subjects from January 2017 to January 2019 in Shandong Tai′an Cancer Prophylaction-Therapeutic Hospital. These patients were randomly divided into observation group (72 cases) and control group (68 cases) using random number table method. The patients in the observation group were treated with oral apatinib combined with S-1 chemotherapy, and the patients in the control group was only given S-1 chemotherapy. The short-term and long-term efficacy and adverse reactions of the two groups were observed.Results:The objective remission rates of the observation group was 38.9% (28/72), higher than that in the control group (22.1%, 15/68), with a statistically significant difference (n χ2=4.655, n P=0.031). The disease control rate of the observation group was 88.9% (64/72), higher than that in the control group (61.8%, 42/68), and there was a significant difference between the two groups (n χ2=13.993, n P<0.001). The median progression-free survival of the observation group and the control group was 5.9 months and 2.7 months respectively, the median overall survival was 14.8 months and 7.9 months respectively, and there were significant differences between the two groups (n χ2=5.477, n P=0.026; n χ2=6.083, n P=0.014). The adverse reactions of the two groups were mild, grade 1-2, mainly including fatigue, leukopenia, hand-foot syndrome, hypertension and proteinuria, with incidences of 59.7% (43/72), 50.0% (36/72), 8.3% (6/72), 12.5% (9/72), 9.7% (7/72) in the observation group, and 51.5% (35/68), 57.4% (39/68), 17.6% (12/68), 4.4% (3/68), 4.4% (3/68) in the control group, there were no significant differences between the two groups (n χ2=0.965, n P=0.326; n χ2=0.760, n P=0.383; n χ2=2.708, n P=0.100; n χ2=2.919, n P=0.088; n χ2=0.794, n P=0.373).n Conclusion:Apatinib combined with S-1 is effective, safe and tolerable in the treatment of recurrent and metastatic esophageal cancer.